Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802881 | 0.82 | KMT2A (0.61) | CNR1MEN1KMT2ACNR2MAPT | |
| SCHEMBL6025511 | 0.82 | MEN1 (0.62) | CNR1MEN1KMT2ACNR2 | |
| SCHEMBL4808041 | 0.81 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL4807383 | 0.80 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL6025473 | 0.80 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL4806129 | 0.78 | KDM4E (0.62) | CNR1MEN1KMT2ACNR2MAPT | |
| SCHEMBL4804885 | 0.78 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL4806164 | 0.76 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL4810403 | 0.76 | CNR1 (0.43) | CNR1MEN1KMT2ACNR2MAPT | |
| SCHEMBL4806021 | 0.75 | CNR1 (0.54) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
| EP-1546115-A2 | SUBSTITUTED PYRIMIDINES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029204-A2 | SUBSTITUTED PYRIMIDINES | MERCK & CO., INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | CNR1 1/4885MEN1 627/4885KMT2A 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.